Want to see TTRX full AI Analyst Report?
Top Page
Turn Therapeutics Inc
(NASDAQ:TTRX)
Select Model
Select Model
Rating:52Neutral
Price Target:
$12.00
▲(21.95% Upside)
Action:Reiterated
Date:10/07/26
The score is held back primarily by weak financial performance (no revenue, widening 2025 losses, and accelerating cash burn) and limited valuation support due to ongoing losses. Technical signals are mixed with mild near-term weakness despite a better longer-term trend, while corporate updates on GX-03 and recent financing provide a meaningful but secondary positive offset.
Positive Factors
GX-03 Phase 2 Progress
GX-03 has advanced from an initial Phase 2 stage into a larger, optimized study with defined efficacy endpoints. This progression improves the program’s ability to generate decision-useful clinical evidence and supports a potentially broader path in inflammatory dermatology, although approval remains unproven.
Negative Factors
No Commercial Revenue
A continuing absence of revenue means the company has not yet demonstrated commercial traction or an internally funded operating model. The materially wider 2025 operating loss shows that development spending is rising ahead of commercialization, leaving earnings visibility dependent on future clinical and regulatory success.
Read all positive and negative factors
Positive Factors
Negative Factors
GX-03 Phase 2 Progress
GX-03 has advanced from an initial Phase 2 stage into a larger, optimized study with defined efficacy endpoints. This progression improves the program’s ability to generate decision-useful clinical evidence and supports a potentially broader path in inflammatory dermatology, although approval remains unproven.
Read all positive factors
Turn Therapeutics Inc (TTRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$357.46M
Dividend YieldN/A
Average Volume (3M)148.73K
Price to Earnings (P/E)―
Beta (1Y)0.20
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees2
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.29
Shares Outstanding29,788,040
10 Day Avg. Volume106,579
30 Day Avg. Volume148,731
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)11.55
Price to Sales (P/S)0.00
P/FCF Ratio-19.94
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.75K
Enterprise Value/Ebitda-51.18
Forecast
1Y Price Target
$15.00Price Target Upside52.44% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$450.00K
Turn Therapeutics Inc Business Overview & Revenue Model
Company Description
Turn Therapeutics Inc., officially known as Global Health Solutions, Inc., is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes. The company utilizes a proprietary drug delivery syste...
Turn Therapeutics Inc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -56.82K | 0.00 | 0.00 | 0.00 |
| EBITDA | -4.17M | -3.14M | -1.72M | -2.25M |
| Net Income | -8.45M | -3.19M | -1.77M | -2.29M |
Balance Sheet | ||||
| Total Assets | 16.96M | 12.16M | 2.05M | 2.01M |
| Cash, Cash Equivalents and Short-Term Investments | 10.29M | 5.08M | 872.60K | 1.18M |
| Total Debt | 6.12M | 80.38K | 121.04K | 25.16K |
| Total Liabilities | 16.27M | 7.48M | 2.23M | 1.93M |
| Stockholders Equity | 686.89K | 4.69M | -177.43K | 85.77K |
Cash Flow | ||||
| Free Cash Flow | -4.32M | -2.72M | -1.46M | -1.42M |
| Operating Cash Flow | -4.32M | -2.56M | -1.36M | -1.38M |
| Investing Cash Flow | -139.26K | -152.99K | -99.47K | -44.31K |
| Financing Cash Flow | 11.56M | 6.92M | 1.15M | 500.00K |
Turn Therapeutics Inc Technical Analysis
Positive
9.84
Price Trends
11.43
Positive
9.25
Positive
6.51
Positive
Market Momentum
0.11
Positive
47.42
Neutral
16.88
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TTRX, the sentiment is Positive. The current price of 9.84 is below the 20-day moving average (MA) of 13.31, below the 50-day MA of 11.43, and above the 200-day MA of 6.51, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 47.42 is Neutral, neither overbought nor oversold. The STOCH value of 16.88 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TTRX.
Turn Therapeutics Inc Risk Analysis
Turn Therapeutics Inc disclosed 54 risk factors in its most recent earnings report. Turn Therapeutics Inc reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Turn Therapeutics Inc Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | $357.46M | -41.18 | -280.41% | ― | ― | ― | |
49 Neutral | $5.33M | -1.33 | -109.26% | ― | -100.00% | 49.19% | |
45 Neutral | $672.63K | ― | -26.63% | ― | 30.12% | -165.46% | |
43 Neutral | $7.87M | -0.10 | -205.45% | ― | ― | 78.16% | |
42 Neutral | $7.18M | -0.05 | 952.76% | ― | -21.49% | 84.62% | |
42 Neutral | $4.10M | -0.23 | -166.67% | ― | ― | 88.77% |
* General Sector Average
TTRX
Turn Therapeutics Inc
12.00
5.49
84.33%
AIM
AIM ImmunoTech
0.18
-2.40
-93.02%
SCNI
Scinai Immunotherapeutics
1.18
-12.42
-91.32%
PULM
Pulmatrix
1.46
-3.44
-70.20%
DRMA
Dermata Therapeutics
1.02
-3.20
-75.83%
AZTR
Azitra Inc
0.13
-0.56
-81.39%
Turn Therapeutics Inc Corporate Events
Business Operations and StrategyProduct-Related Announcements
Turn Therapeutics Updates GX-03 Program and Pipeline Outlook
Positive
Oct 7, 2026
On October 6, 2026, Turn Therapeutics Inc. released an updated corporate investor presentation detailing the status of its GX-03 program and broader pipeline. The presentation underscores GX-03 as a non-steroid, non-systemic IL-36 and IL-31 inhibi...
Business Operations and Strategy
Turn Therapeutics to Present Atopic Dermatitis Strategy
Positive
Sep 10, 2026
On September 10, 2026, Turn Therapeutics announced that Chief Executive Officer Bradley Burnam and Executive Clinical and Regulatory Lead Stephen M. Hahn, M.D., will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September...
Business Operations and StrategyExecutive/Board Changes
Turn Therapeutics Names Robert Redfield Chief Scientific Officer
Positive
Sep 9, 2026
On September 9, 2026, Turn Therapeutics appointed former U.S. Centers for Disease Control and Prevention director Robert R. Redfield, M.D., as Chief Scientific Officer. Redfield, an internationally recognized physician-scientist with more than fou...
Business Operations and StrategyPrivate Placements and Financing
Turn Therapeutics Reports Unregistered Cashless Warrant Share Issuance
Neutral
Aug 18, 2026
On October 8, 2025, Turn Therapeutics Inc. issued a warrant to GEM Yield Bahamas Limited to purchase 1,192,207 shares of common stock, representing 4% of the company’s fully diluted outstanding shares at a warrant price of $5.03 per share, u...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Turn Therapeutics Raises $1.35M Through Private Placement
Positive
Aug 17, 2026
On August 14, 2026, Turn Therapeutics Inc. entered into securities purchase agreements with accredited series and seed investors to sell 135,000 shares of its common stock at $10.00 per share, raising gross proceeds of $1.35 million. The transacti...
Business Operations and StrategyProduct-Related Announcements
Turn Therapeutics Updates GX-03 Investor Presentation and Pipeline
Positive
Jul 28, 2026
On July 28, 2026, Turn Therapeutics released an updated investor presentation highlighting progress on GX-03, a first-in-class, non-steroidal topical immunomodulator targeting IL-36, IL-31 and related cytokines for moderate to severe atopic dermat...
Business Operations and StrategyProduct-Related Announcements
Turn Therapeutics advances GX-03 Phase 2 eczema program
Positive
Jul 7, 2026
On July 7, 2026, Turn Therapeutics announced completion of a comprehensive interim analysis of its adaptive Phase 2 trial of GX-03 in atopic dermatitis and unveiled the final Stage 2 design. The review showed clinically meaningful efficacy across ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.